{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:17Z","timestamp":1781643437166,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alexion, Rare Disease Company of AstraZeneca","award":["Alexion, Rare Disease Company of AstraZeneca"],"award-info":[{"award-number":["Alexion, Rare Disease Company of AstraZeneca"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is currently limited data to guide treatment selection, dosing, combination strategies and sequencing in the management of myasthenia gravis (MG). Additionally, MG symptoms are heterogenous between people and with time, requiring an individualized treatment approach. As such, successful patient-physician communication is key. This Delphi project was undertaken by MG specialists and patient representatives to explore their opinion on improving MG management via effective physician-patient communication and collaboration approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This mixed-methods study was conducted in two phases. In Phase I, seven MG specialists and two patient representatives contributed to idea generation. Relevant insights informed the development of the Phase II Delphi survey. A panel of 16 MG specialists and seven patient representatives participated in a two-round Delphi survey. Consensus was defined as \u2265\u200970% agreement or disagreement on a 6-point Likert scale. Participants responded to the survey from what they considered an ideal scenario, regardless of their real-world experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Consensus was achieved on 89% of all statements. Key areas of alignment were \u2013 importance of incorporating patient preferences on quality of life (QoL), sustained symptom control, route of administration, and side effects profile. Both groups agreed that current clinical practices insufficiently integrate mental health considerations and patient engagement remains suboptimal. Two key areas of misalignment were \u2013 patient representative and physicians had different perspective on how well physicians understood patient preferences and both groups showed different interpretations of side effects (adverse reaction versus issues of tolerability).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This Delphi consensus found that while physician and patient representatives shared similar perspectives these were not always reflected in current clinical practice due to differences in understanding of patient preferences. Prioritizing structured conversations on QoL, treatment expectations, and side effect were found important for physicians while improving access to information, openly communicating and actively participating in treatment decisions were key outcomes for patients. This study lays a valuable foundation for deepening conversations and alignment on key topics in MG management among the medical, patient and caregiving communities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04312-7","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:25:21Z","timestamp":1773984321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the gap between patient and physician perspectives on management of generalized myasthenia gravis: a Delphi consensus study"],"prefix":"10.1186","volume":"21","author":[{"given":"Andrew","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kaempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang N.","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Voerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Frostell-Pyh\u00e4j\u00e4rvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Atula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"4312_CR1","doi-asserted-by":"publisher","first-page":"1223322","DOI":"10.3389\/fimmu.2023.1223322","volume":"14","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wang B, Hao Y, Zhu R. Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases. Front Immunol. 2023;14:1223322.","journal-title":"Front Immunol"},{"key":"4312_CR2","first-page":"874680","volume":"2012","author":"A Jayam Trouth","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012:874680.","journal-title":"Autoimmune Dis"},{"issue":"8","key":"4312_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473\u201394.","journal-title":"J Neurol"},{"issue":"26","key":"4312_CR4","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"4312_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311\u201337.","journal-title":"Neurol Clin"},{"key":"4312_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","volume":"11","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020;11:538.","journal-title":"Front Neurol"},{"key":"4312_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S377056","volume":"12","author":"SS Nair","year":"2023","unstructured":"Nair SS, Jacob S. Novel Immunotherapies for Myasthenia Gravis. Immunotargets Ther. 2023;12:25\u201345.","journal-title":"Immunotargets Ther"},{"issue":"5","key":"4312_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr., Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"issue":"7","key":"4312_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"8","key":"4312_CR10","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","volume":"270","author":"A Meisel","year":"2023","unstructured":"Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. 2023;270(8):3862\u201375.","journal-title":"J Neurol"},{"key":"4312_CR11","doi-asserted-by":"crossref","unstructured":"Habib AA, Druzdz A, Grosskreutz J, Mantegazza R, Sacconi S, Utsugisawa K et al. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. J Neuromuscul Dis. 2025:22143602241308181.","DOI":"10.1177\/22143602241308181"},{"issue":"12","key":"4312_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4312_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13023-023-02727-0","volume":"18","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, DeCourcy J, Golden K, Gibson G, Taylor C, et al. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey. Orphanet J Rare Dis. 2023;18(1):169.","journal-title":"Orphanet J Rare Dis"},{"key":"4312_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7525-8-129","volume":"8","author":"S Twork","year":"2010","unstructured":"Twork S, Wiesmeth S, Klewer J, Pohlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"4312_CR15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K. The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis. Neurol Ther. 2021;10(2):1103\u201325.","journal-title":"Neurol Ther"},{"issue":"9","key":"4312_CR16","doi-asserted-by":"publisher","first-page":"e70081","DOI":"10.1002\/hsr2.70081","volume":"7","author":"M Yung","year":"2024","unstructured":"Yung M, Narayanaswami P, Pesa J, Choudhry Z, Jackson L, Deering KL, et al. Patient and care partner perspectives and preferences related to myasthenia gravis treatment: A qualitative study. Health Sci Rep. 2024;7(9):e70081.","journal-title":"Health Sci Rep"},{"issue":"4","key":"4312_CR17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40120-025-00751-9","volume":"14","author":"C Reyes Acosta","year":"2025","unstructured":"Reyes Acosta C, Vlaev I, Rodriguez A, Foss A, Pinto A, Hewamadduma C, et al. What Patients Don\u2019t Say and Physicians Don\u2019t Ask: A Needs Assessment in Myasthenia Gravis Integrating Patient and Healthcare Professional Perspectives. Neurol Ther. 2025;14(4):1419\u201338.","journal-title":"Neurol Ther"},{"issue":"6","key":"4312_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mus.26850","volume":"61","author":"MK Hehir","year":"2020","unstructured":"Hehir MK, Punga AR, Ciafaloni E. Myasthenia gravis patient and physician opinions about immunosuppressant reduction. Muscle Nerve. 2020;61(6):767\u201372.","journal-title":"Muscle Nerve"},{"key":"4312_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA. A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature. Front Neurol. 2020;11:604.","journal-title":"Front Neurol"},{"key":"4312_CR20","doi-asserted-by":"publisher","first-page":"1214041","DOI":"10.3389\/fneur.2023.1214041","volume":"14","author":"T Sobierajski","year":"2023","unstructured":"Sobierajski T, Lasek-Bal A, Krzystanek M, Gilhus NE. Diagnosis and therapy of myasthenia gravis-the patients\u2019 perspective: a cross-sectional study. Front Neurol. 2023;14:1214041.","journal-title":"Front Neurol"},{"issue":"5","key":"4312_CR21","doi-asserted-by":"publisher","first-page":"e068104","DOI":"10.1136\/bmjopen-2022-068104","volume":"13","author":"S Berrih-Aknin","year":"2023","unstructured":"Berrih-Aknin S, Palace J, Meisel A, Claeys KG, Muppidi S, Sacca F, et al. Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG). BMJ Open. 2023;13(5):e068104.","journal-title":"BMJ Open"},{"issue":"6","key":"4312_CR22","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1016\/j.jval.2023.03.1848","volume":"26","author":"J Pesa","year":"2023","unstructured":"Pesa J, Choudhry Z, De Courcy J, Barlow S, Chatterton E, Birija SL, et al. PCR70 Patient and Physician Concordance in Treatment Satisfaction and Symptom Severity Among Male and Female Myasthenia Gravis Patients in the United States and Five European Countries. Value Health. 2023;26(6):S324.","journal-title":"Value Health"},{"issue":"1","key":"4312_CR23","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1038\/s41598-024-57825-1","volume":"14","author":"A Anderson","year":"2024","unstructured":"Anderson A, Pesa J, Choudhry Z, Brethenoux C, Furey P, Jackson L, et al. Patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations. Sci Rep. 2024;14(1):7271.","journal-title":"Sci Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04312-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04312-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04312-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:32:19Z","timestamp":1781641939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04312-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4312"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04312-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not require ethical approval as it did not involve the collection of personal or sensitive data. Nevertheless, a compulsory informed consent declaration was included at the beginning of the questionnaire. Consent was considered implied through participants\u2019 voluntary engagement and completion of the questionnaire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Medical writing support was provided by our colleagues at Cytel.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical writing and editorial assistance"}},{"value":"AC has received speakers\u2019\/board honoraria from Alexion, Biogen, BMS, Genzyme, Horizon, Janssen\/J&J, Merck KGaA, Novartis, Roche, Sanofi, Teva and UCB, all for hospital research funds. AC has received research support from Biogen, CSL Behring, Genzyme, Novartis and UCB, the European Union, and the Swiss National Foundation and serves as associate editor of the European Journal of Neurology, and on the editorial board for Clinical and Translational Neuroscience. WNL has received honoraria for presentations and\/or advisory roles from Alexion, Argenx, UCB, Janssen, Amgen, Alnylam, Sanofi, Amicus, Lupin, Biogen and Roche and holds a research grant from Pfizer. JV has worked on advisory boards or received speaker honoraria from Roche, Regeneron, Toleranzia, Hansa Biopharma, Argenx BVBA, UCB Biopharma SPRL, Amgen, Dianthus Therapeutics, NMD Pharma, Alexion Pharmaceuticals, Novartis Pharma AG, Johnson & Johnson. SA has received speaker honoraria or served as a consultant on advisory boards for Alexion, ArgenX, Sanofi Genzyme, Biogen, UCB Pharma and Merck.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}